Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio.
Biotechnology and pharmaceutical company Moderna, most recently known for the mRNA therapeutic and vaccine innovations, has announced a definitive agreement with OriCiro to acquire Tokyo-based genomics services company OriCiro Genomics.
In a USD $85 million deal, the acquisition of OriCiro and its technologies will support Moderna’s existing portfolio of mRNA manufacturing capabilities for therapeutics and vaccines. CEO of Moderna Stephane Bancel comments that “With this acquisition, we obtain best-in-class tolls for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing... OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the Oriciro team to Moderna.”
Moderna’s current clinical portfolio spans seven modalities including mRNA and lipid nanoparticle formulation. With an integrated manufacturing plant that can allow for clinical and commercial production at scale, Moderna became one of the earliest companies to manufacture the authorised use and approval of a COVID-19 vaccine. OriCiro’s focus on the development and commercialisation of cell-free synthesis and the amplification of plasmid DNAs for use in cell and gene therapies will place Moderna in a position to expedite the research, development, and commercial manufacturing of advanced cell and gene therapeutics.
President and co-founder of OriCiro Seiji Hirasaki commented on the acquisition: “We are thrilled to join forces with Moderna to realise the full power of OriCiro for the benefit of patients.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance